Aurora Partners with Leafio to Expand Medical Cannabis Reach in Australia

EDMONTON – Aurora Cannabis Inc. disclosed a new wholesale distribution agreement with Leafio, the supply chain arm of Montu Australia, positioning the Canadian producer to channel more of its medical Cannabis lineup into clinics and pharmacies across the continent.

The deal, struck through Aurora’s local unit MedReleaf Australia, grants Leafio rights to handle sales of flagship brands including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed. These offerings, certified under Australia’s Therapeutic Goods Administration standards, target conditions from chronic pain to epilepsy, tapping into an approx. 700,000-patient base that has swelled with rising prescriptions.

“We are excited to join forces with Leafio to improve access to consistent, high-quality medical Cannabis for Australian patients,” said Stanley Sack, interim managing director at MedReleaf Australia. He highlighted the match between Aurora’s production rigor and Leafio’s network, which spans over 4,000 healthcare providers nationwide.

Leafio’s general manager, Nicole Le Maistre, echoed the synergy: “Together, Leafio and Aurora can reach more Australian patients through trusted medical channels, bolstering access to world-class products and expertise.” The collaboration extends beyond mere logistics, folding in joint efforts on clinician training and product research to refine treatment protocols.

This step arrives as Aurora reports a record quarter for its medical segment, with global medical Cannabis net revenue up 15% year-over-year to $70.5 million, fueled partly by international footholds like Australia. The local market, pegged at $740 million last year, stands to double in scale by 2033 under a 7.1% CAGR – a trajectory built on regulatory nods for unapproved therapies and a doctor community warming to Cannabis as an opioid alternative. Yet challenges persist. Import reliance keeps costs elevated, and fragmented prescribing habits demand sharper education to convert awareness into steady demand.

Aurora’s play here signals a deliberate pivot toward stable, high-margin medical channels over recreational bets, a pattern evident in its trimmed domestic operations back home. By leaning on Leafio’s established routes, which already move goods to remote outposts, the company sidesteps the steep upfront costs of building from scratch, potentially lifting its Australian sales slice from single digits toward double in the next fiscal year.

For investors eyeing Aurora’s $258 million market cap and $4.54 share price, this adds a layer of predictability to an otherwise volatile sector. It also underscores Australia’s pull as a bellwether: a tightly regulated haven where evidence trumps hype, and partnerships like this one gradually reshape supply chains.